Clinical Trials Browser

Interventional × Glioblastoma × pazopanib × Clear all

Glioblastoma

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

31 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT03275558 2018-07-19

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Phase 1 Withdrawn

CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00350727 2013-04-19

VEG102857

Phase 2 Completed

75 enrolled 45 charts

CNS

Glioblastoma, Glioma, Recurrence

Clinical Trials

PAZOGLIO

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

HYPAZ

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Pazopanib in Treating Patients With Recurrent Glioblastoma

VEG102857